The Center for Biosimilars® recaps the top stories for the week of September 23, 2019.
Transcript
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 23, 2019.
Number 5: Generium has received approval for the first biosimilar dornase alfa, which treats cystic fibrosis, in Russia.
Number 4: A newly published paper concludes that, as experience and analytical capabilities mature, there will be a reduced requirement for clinical data in biosimilar development.
Number 3: Two biosimilar bills, both with bipartisan sponsors, were unveiled last week.
Number 2: The Committee for Medicinal Products for Human Use issued a positive opinion for Celltrion’s subcutaneously administered biosimilar infliximab for the treatment of rheumatoid arthritis.
Number 1: The FDA has released a new suite of resources to educate patients about biosimilars.
Finally, last week, our e-newsletter asked whether you think that the 2020 launch of authorized generics of 2 of Novo Nordisk’s insulin products will help patients afford their medication.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.